XtalPi Submitted IND for Gut-Restricted Pain Drug
The company has filed an application to test a targeted TRK inhibitor for chronic intestinal pain in clinical trials.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Do you believe using AI in drug discovery will lead to better treatments for chronic pain?
XtalPi has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for KQTD-126, its first internally developed candidate. This drug is a gut-restricted pan-TRK inhibitor designed to address chronic pain in patients with irritable bowel syndrome and inflammatory bowel disease.
Why it matters
Systemic TRK inhibitors currently carry a high risk of neurological side effects, leaving chronic abdominal pain as a significant unmet clinical need. This filing signals a shift toward using AI-designed molecules to achieve tissue-specific action in the gut.
Preclinical data indicate that the AI-designed KQTD-126 achieves sub-nanomolar potency. It is engineered to bypass systemic circulation to avoid the neurological side effects typically associated with broad-spectrum TRK inhibitors.
The players
XtalPi
A research company utilizing a proprietary platform that combines generative AI with automated robotics for drug discovery.
The details
The drug was developed by integrating generative AI models with a fleet of automated chemistry robots. This process enabled the rapid iterative cycle of computational design, automated synthesis, empirical screening, and molecular refinement to isolate a compound that remains restricted to the gastrointestinal tract. A pan-TRK inhibitor is a therapeutic agent that blocks the tropomyosin receptor kinase (TRK) family of enzymes involved in pain signaling pathways.
Timeline
September 25, 2026: XtalPi submitted the IND application to the FDA.
The Tech Race
This submission marks the first IND application from the internal drug discovery pipeline of XtalPi. It reflects a broader industry race to move beyond using AI as a platform for partner services toward establishing a proprietary clinical-stage portfolio.
This development is in the research stage and does not currently impact patient treatment options. The project represents a long-term effort to provide a safer alternative to existing systemic pain inhibitors for the millions of people living with IBD and IBS.
The takeaway
The transition of this molecule from lab-bench discovery to the FDA filing process highlights the maturing capabilities of AI-driven drug design. Analysts and researchers should watch for the FDA response to this IND to determine the next phase of human trials for the candidate.
Further reading
For more on the latest research in drug development, visit Biotech.
Live Poll
Do you believe using AI in drug discovery will lead to better treatments for chronic pain?
